The present disclosure provides materials and methods for identifying patients that are at risk of progression to clinically significant COVID-19 infection or disease.

The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

Methods are provided for making rapid labeled dextran ladders and other calibrants useful in liquid chromatography. The methodologies include a two-step process comprising a reductive amination step of providing a reducing glycan and reacting it with a compound having a primary amine to produce an intermediate compound. The intermediate compound is then rapidly tagged with a rapid tagging reagent to produce the rapid labeled dextran ladder.

[Problem] To provide a signal enhancer that enhances a signal based on reaction between an α1-6 fucose sugar chain and an α1-6 fucose specific lectin bound thereto, a method for using the same, and use of the same.

[Solution] A signal enhancer enhances a signal based on reaction between an α1-6 fucose sugar chain and an α1-6 fucose specific lectin bounded thereto, and is characterized by having, as an active ingredient, at least one selected from the group consisting of urea and thiourea. The final concentration of the urea is preferably 1-9 M and the final concentration of the thiourea is 0.1-1.5 M. Since the signal enhancer allows accurate measurement of an α1-6 fucose sugar chain, the signal enhancer is greatly useful in detection and determination of a disease related to an α1-6 fucose sugar chain and in academic study of an α1-6 fucose sugar chain.

The claimed invention provides personalized glucose and insulin information to a user in need thereof. Non-invasive body fluid capture techniques utilize saliva to provide body levels of glucose and insulin as well as optional pharmaceutical ingestion coordinated over time. Saliva captured on cellulose strips are analyzed in real time using oxidation and aptamer conjugate hybridization together with traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated against time of pharmaceutical administration. By embracing the P4 (Participatory, Personalized, Predictive, and Preventive) health management method the patient can determine glucose and insulin related wellness levels and if a pharmaceutical is having the correct and desired effect for maximum therapeutic benefit.

Disclosed herein are methods and compositions involved in identifying cells that lack apico-basal polarity as well as methods and compositions involved in selectively delivering payload molecules to cells that lack apico-basal polarity, and methods of selecting test compounds that restore apico-basal polarity.

[Problem] The purpose of the present invention is to stably supply high-quality and highly uniform Wisteria floribunda agglutinin (WFA) that recognizes biologically important sugar-chain markers, to elucidate the sugar-chain recognition activity in detail, and to furthermore increase the specificity of the sugar-chain recognition activity. [Solution] The present invention involves the development of a technique for cloning genes for coding Wisteria floribunda agglutinin (WFA) and producing recombinant WFA having the same sugar-chain recognition activity as natural WFA from transformed bacteria. Natural WFA is reduced to thereby manufacture a reduced WFA monomer for specifically recognizing terminal GalNAc residue. A recombinant monomer WFA for recognizing LDN (GalNAcβ1, 4GlcNAc) sugar chain, which is important as a diagnostic marker among sugar chains having a terminal GalNAc residue, is manufactured by introducing cysteine mutation to recombinant WFA or by C-terminal-side amino acid deletion.

Cyclic-GMP-AMP (cGAMP), including 2′,3′-cGAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).

Provided is a method for quantitating a saccharide in a liquid sample. The method comprises incubating the liquid sample with 2,3-naphthalenediamine in the presence of iodine to allow a naphthimidazole group to be linked to the saccharide to obtain a first mixture; obtaining an .sup.1H-NMR spectrum of the first mixture; and comparing, in said .sup.1H-NMR spectrum, the intensity or integral of a proton signal corresponding to the saccharide to the intensity or integral of a proton signal corresponding to an internal standard present in the first mixture.